JCO Global Oncology (Dec 2021)

SARS-CoV-2 Infection Rate in Patients With Cancer and Health Care Workers in a Chemoradiotherapy Unit During the Pandemic: A Prospective Cohort in Mexico

  • Monica Isabel Meneses-Medina,
  • Jorge Humberto Hernandez-Felix,
  • Luis Guillermo Anaya-Sánchez,
  • Ana Karen Valenzuela-Vidales,
  • Vanessa Rosas-Camargo,
  • Edgar Omar Martos-Armendariz,
  • Lucero Itzel Torres-Valdiviezo,
  • Alberto Cedro-Tanda,
  • Alejandro Noguez-Ramos,
  • Luis Alonso Herrera-Montalvo,
  • Alfredo Hidalgo-Miranda,
  • Raymundo David Valdez-Echeverria,
  • Arturo Galindo-Fraga,
  • Fidel David Huitzil-Meléndez

DOI
https://doi.org/10.1200/GO.21.00207
Journal volume & issue
no. 7
pp. 1639 – 1646

Abstract

Read online

PURPOSECancer treatment during the COVID-19 pandemic represents a challenge. Hospital visits to receive treatment and interaction with health care workers (HCW) represent potential contagious events. We aimed to determine SARS-CoV-2 infection rate among patients with cancer and HCW of a chemoradiotherapy unit localized in a center designated as a COVID-19 priority facility in Mexico City. We also determined the diagnostic performance of a clinical questionnaire (CQ) as a screening tool and anti–SARS-CoV-2 antibody seroconversion rate.METHODSHCW and patients with solid tumors attending the chemoradiotherapy unit signed informed consent. To determine SARS-CoV-2 infection rate prospectively, a nasopharyngeal swab for SARS-CoV-2 real-time quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) was performed every 2 weeks in asymptomatics. An electronic CQ interrogating COVID-19–related symptoms was sent daily. Anti–SARS-CoV-2 immunoglobulin G (IgG) antibodies were measured at baseline and at the end of the study period.RESULTSFrom June to September 2020, we included 130 asymptomatic participants, 44.6% HCW and 55.4% patients with cancer. During a median follow-up of 85 days, 634 nasopharyngeal swabs were performed. Average SARS-CoV-2 monthly incidence was 4.6% (3.15%-7.47%), and cumulative infection rate was 13.8% (18 of 130). Cases were mostly asymptomatic (66%), and no hospitalizations or deaths were recorded. The CQ as a screening tool provided a sensitivity of 27.7%, a positive predictive value of 26.3%, and a positive likelihood ratio of 12. SARS-CoV-2 IgG seroconversion rate was 27.7% among those with a positive RT-PCR.CONCLUSIONPatients with cancer on treatment can have uncomplicated COVID-19 outcomes. Biweekly RT-qPCR testing detects asymptomatic infections, prevents transmission, and should be implemented in units to increase patient safety. CQ increase RT-qPCR diagnostic yield and may prioritize testing in resource-deprived settings. Post-infection IgG seroconversion is unreliable.